SPY330.06+1.27 0.39%
DIA268.41+1.69 0.63%
IXIC10,941.17+38.37 0.35%

FDA Panel Votes 14-2 Against Approval Of Eli Lilly And Boehringer Ingelheim's Empagliflozin As An Add On To Insulin Therapy For Type 1 Diabetes

-Reuters

Reuters · -